Crispr Therapeutics’ revenue and earnings trends
Crispr Therapeutics (CRSP) has risen 130.62% YTD (year-to-date). This leading gene-editing company is focused on leveraging the CRISPR-Cas9 technology for developing therapies that target multiple hematology, immune-oncology, liver, and other organ-related indications.
In Q2 2018, Crispr Therapeutics reported revenues of $1.09 million, which was a YoY (year-over-year) decline of 69.6%, missing the consensus estimate by $0.74 million. It also reported EPS of -$0.82, which was lower than the consensus estimate by -$0.19. The company, however, has a robust patent portfolio and had $319.7 million in cash on its balance sheet at the end of June.
The above diagram gives a snapshot of Crispr Therapeutics’ intellectual property landscape.
Crispr Therapeutics has already secured approval for clinical trial applications to evaluate CTX001, an investigational allogeneic CAR (chimeric antigen receptor) T-cell therapy, in severe combined immunodeficiency and beta-thalassemia indications. The company, along with its partner Vertex Pharmaceuticals (VRTX), expects to begin the Phase 1/2 trial for CTX001 in the beta-thalassemia indication in late 2018.
Revenue and earnings estimates
Wall Street analysts expect Crispr Therapeutics to report revenues of $9.1 million in 2018, which would be a YoY (year-over-year) decline of 77.8%. However, the company is expected to see more than 100% YoY revenue growth in 2019. It’s expected to report revenues of $21.7 million and $25.24 million in 2019 and 2020, respectively.
In Q3 2018, analysts expect Crispr Therapeutics to report revenues of $3.25 million, which is a YoY rise of 36.15%. It’s also expected to report a loss per share of $0.73 in the third quarter, which is 17.74% higher YoY.